BSX
Boston Scientific Corp
42.60$
-1.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.8% | 25.7% | 4.3% | 19.7% | 23.8% | 31.9% | 11.6% | 25.4% | 26.5% | 25.8% | 6.7% | 27.1% | 21.6% | |
| 8.5% | 8.4% | 7.9% | 7.5% | 15.1% | 7.6% | 7.0% | 6.6% | 6.8% | 6.9% | 6.7% | 6.5% | 6.7% | |
| 1.7% | 1.6% | 1.6% | 4.7% | -1.4% | 1.5% | 1.6% | 1.5% | 1.6% | 1.3% | 1.6% | 1.6% | 1.5% | |
| 2.0% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -5.0% | -1.5% | -19.3% | -5.1% | 3.9% | 7.1% | -14.5% | 4.6% | 0.9% | 2.9% | -17.6% | 1.4% | -3.1% | |
| 5.8% | 7.2% | 6.4% | 3.8% | 7.2% | 6.4% | 4.0% | 3.8% | 3.6% | 6.6% | 3.4% | 3.6% | 4.3% | |
| -5.6% | -28.3% | -7.4% | -6.6% | -33.9% | -81.2% | -10.7% | -22.2% | -9.9% | -9.7% | -11.4% | -35.9% | -17.0% | |
| 0.8% | 0.5% | 0.0% | 0.0% | 0.5% | 0.0% | – | – | – | – | – | – | – | |
| 4.7% | 3.2% | 2.1% | – | -1.5% | 5.0% | 2.5% | 2.9% | 5.2% | 5.3% | – | -36.8% | – | |
| -1.2% | – | – | – | 0.0% | 4.1% | 5.3% | -6.2% | -4.2% | -4.0% | -5.0% | 30.5% | 4.7% | |
| 0.5% | 0.4% | 40.7% | 0.6% | 0.2% | 4.7% | 5.0% | -6.7% | -2.1% | -3.5% | -5.0% | -7.5% | -4.6% | |
| 14.5% | -2.1% | 37.4% | 13.7% | -9.8% | -44.8% | 6.7% | -3.5% | 14.4% | 12.7% | -10.0% | -16.4% | 0.0% | |
| 13.9% | 18.5% | -2.1% | 16.0% | 16.6% | 25.5% | 7.6% | 21.7% | 22.9% | 19.2% | 3.3% | 23.5% | 17.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.